Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An inherited disorder of peptide metabolism characterized by severe skin lesions, recurrent infections (involving mainly the skin and respiratory system), dysmorphic facial features, variable cognitive impairment, and splenomegaly.
Features include always present findings: Enlarged liver (hepatomegaly), Recurrent infections, Prominent forehead, and Hypertelorism and others; and very common findings: Elevated antibody levels (increased circulating immunoglobulin concentration). 34 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 5 | Diffuse telangiectasia, Skin ulcer, Crusting erythematous dermatitis |
PEPD function has not been fully characterized.
Prolidase deficiency is caused by mutations in the PEPD gene on chromosome 19.
No consensus clinical diagnostic criteria for prolidase deficiency have been published.
Prolidase deficiency should be suspected in individuals with the following clinical, biochemical, other supportive laboratory, and family history findings.
Clinical findings
Source: GeneReviews — "Prolidase Deficiency"
No approved treatments are currently available for prolidase deficiency. The disease remains an area of unmet medical need.
Gene therapy approaches for prolidase deficiency have been reported in the published literature.
No clinical practice guidelines for prolidase deficiency have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with prolidase deficiency, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Prolidase Deficiency
Table 6. Recommended Surveillance for Individuals with Prolidase Deficiency
System/Concern |
|---|
No clinical trials have been registered for prolidase deficiency.
18 publications have been identified in PubMed for prolidase deficiency. Research spans Case Report / Case Series (67%), Other (11%), and Review / Meta-Analysis (6%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 12 | 67% |
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Blood and immune system |
4 |
Recurrent infections, Low red blood cell count (anemia), Enlarged spleen (splenomegaly) |
Brain and nerves | 4 | Mild global developmental delay, Febrile seizure (within the age range of 3 months to 6 years), Global developmental delay |
Lungs and breathing | 3 | Chronic lung disease, Recurrent pneumonia, Asthma |
Digestive system | 3 | Enlarged liver (hepatomegaly), Prolonged neonatal jaundice, Enlarged spleen (splenomegaly) |
Head and neck | 2 | Facial hirsutism, High palate |
Lab test results | 2 | Elevated antibody levels (increased circulating immunoglobulin concentration), Elevated circulating aspartate aminotransferase concentration |
Growth and development | 1 | Failure to thrive |
Pregnancy and birth | 1 | Prolonged neonatal jaundice |
Eyes | 1 | Ptosis |
Age of onset: infancy.
To date, more than 175 individuals from more than 90 families have been identified with prolidase deficiency, as recently reviewed by and . The following description of the phenotypic features associated with this condition is based on these reviews. Note: A minority of individuals (n=5) have remained asymptomatic, despite biochemical or molecular confirmation of prolidase deficiency [, , , , ]. However, limited long-term information is available on these individuals; the oldest asymptomatic individual was 29 years old at the time of report. Table 2. Prolidase Deficiency: Frequency of Select Features
Feature | % of Personsw/Feature | Comment |
|---|---|---|
Dysmorphic facial features | 66% | — |
Skin ulcers | 62% | Most commonly affecting lower extremities, particularly feet |
ID/DD | 58% | IQ ranging from 30 to 901 in those who have undergone IQ testing (n=18) |
Recurrent infections | 48% | Commonly sinopulmonary infections or gastroenteritis |
Organomegaly | 45% | Mostly splenomegaly, rarely (14%) accompanied by hepatomegaly |
Skeletal findings | 34% | Incl hand/feet (14%) other limb (6%) abnormalities, osteopenia (7%), joint hypermobility (7%), or arthritis (5%) |
Anemia | 30% | — |
Thrombocytopenia | 18% | — |
Chronic pulmonary disease | 12% | Excl asthma (7%) |
Autoimmune disease | 12% | Incl SLE or SLE-like features, rhupus,2 autoimmune GI disease or arthritis |
Hypergammaglobulinemia | 15% | Incl hyper IgG hyper IgE DD = developmental delay; GI = gastrointestinal; ID = intellectual disability; IgG = immunoglobulin G; IgE = immunoglobulin E; SLE = systemic lupus erythematosus The formal medical definition of intellectual disability is an IQ score lower than 70. |
Source: GeneReviews — "Prolidase Deficiency"
Disorders with imidodipeptiduria. Imidodipeptiduria has been described in bone disorders, presumably originating from collagen under conditions of high bone turnover [, , , ]. Genetic disorders with skin ulcers and/or hyper IgE. See . Table 3. Genetic Disorders with Skin Ulcers and/or Immune Deficiency in the Differential Diagnosis of Prolidase Deficiency
Gene | DiffDx Disorder | MOI | Key Features of DiffDx Disorder | Distinguishing Features |
|---|---|---|---|---|
DOCK8 | DOCK8 deficiency (DOCK8 AR HIES) (OMIM 243700) | AR | Primary immune deficiency syndrome characterized by serum concentration of IgE, severe eczema, recurrent skin lung infections, all of which can also be seen in prolidase deficiency. | In DOCK8-HIES: incidence of neurologic abnormalities, occurrence of viral infections of skin (e.g., Molluscum contagiosum, warts) virus-driven malignancies.Note: Nonimmunologic findings of STAT3-HIES (e.g., connective tissue, skeletal, dental involvement) are absent in DOCK8-HIES.1 |
HBB | Sickle cell disease (SCD) | AR | Intermittent vaso-occlusive events chronic hemolytic anemia. Persons w/highest rates of hemolysis are predisposed to leg ulcers. | In SCD: While urinary excretion of hydroxyproline has been significantly in persons w/SCD compared to controls2 (presumably due to bone involvement), glycylprolinuria has not been reported. |
Beta-thalassemia | AR | synthesis of hemoglobin subunit beta that amounts of hemoglobin A, microcytic hypochromic anemia, abnormal peripheral blood smear w/nucleated red blood cells. Leg ulcers are reported in untreated or poorly transfused persons w/beta-thalassemia. | Imidopeptiduria is not known to occur in beta-thalassemia. Persons w/prolidase deficiency should have normal hemoglobin electrophoretic pattern. | — |
STAT3 | STAT3 hyper IgE syndrome (STAT3-HIES) | AD | Primary immune deficiency syndrome characterized by serum IgE, eczema, recurrent skin respiratory tract infections, together w/nonimmune features. | Mucocutaneous candidiasis is frequent in STAT3-HIES, but not commonly reported in prolidase deficiency. Retention of primary teeth bone fractures following minimal trauma are also distinguishing features of STAT3-HIES. WRN |
Werner syndrome | AR | Cancer predisposition premature appearance of features assoc w/normal aging. Findings shared by prolidase deficiency Werner syndrome: chronic lower-extremity ulcers, premature graying of hair, "bird-like" facial appearance. | — | — |
Source: GeneReviews — "Prolidase Deficiency"
Genetic testing for PEPD is available. Testing is considered confirmatory for diagnosis.
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measurement of growth parameters | To assess for abnormal growth, short stature, microcephaly |
Skin | Full skin exam | Consider consultation w/wound care specialist. |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education |
Neurologic | Neurologic eval | Consider brain MRI if clinically indicated.; Consider EEG if seizures are a concern. |
Gastrointestinal | Physical exam to assess for hepatosplenomegaly | If present, perform abdominal ultrasound to assess extent. Measurement of liver enzymes (AST/ALT) |
Hematologic | Complete blood count | To assess for anemia thrombocytopenia |
Immunologic | Quantitative immunoglobulins | To assess for hyperimmunoglobulinemia Consider eval for autoimmune condition in presence of consistent clinical signs/symptoms. |
Cardiac | Assess for any pulmonary issues. | If present, consider:; Chest imaging, including chest x-ray;; Pulmonary function tests;; Echocardiogram to assess for pulmonary hypertension. |
Musculoskeletal | Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:; Gross motor fine motor skills Bone health assessment should be considered on individual basis. |
Eyes | Ophthalmologic eval | To assess for BCVA, refractive errors, optic nerve abnormalities, more complex findings that may require subspecialty referral. |
ENT/Mouth | Dental eval | For dental anomalies (in those whose teeth have erupted) Genetic |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of prolidase deficiency to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with Prolidase Deficiency Manifestation/Concern | Treatment | Considerations/Other |
Skin ulcers1 | Standard treatment by wound care specialist | Topical proline (often 5%) ointment w/liquid paraffin applied w/dressing changes |
DD/ID | See . | — |
Epilepsy | Standardized treatment w/ASM by experienced neurologist | No ASM has been demonstrated effective specifically for this disorder. |
Hepatosplenomegaly | No specific treatment is typically available. | Avoid contact sports. Anemia/ Thrombocytopenia |
Source: GeneReviews — "Prolidase Deficiency"
View trials for prolidase deficiency
Evaluation
Frequency |
|---|
Constitutional | Measurement of growth parameters | At each visit Development |
ENT/Mouth | Dental eval | Every 6 mos after tooth eruption Gastrointestinal |
Eyes | Ophthalmology eval | Annually or as clinically indicated Family/ |
Community | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit OT = occupational therapy; PT = physical therapy |
Source: GeneReviews — "Prolidase Deficiency"
Phenotype severity distribution: 11 always present features, 1 very common feature, 8 common features.
Estimated prevalence: Unknown (Unknown prevalence).
2 |
11% |
Research summaries | 1 | 6% |
Laboratory research | 1 | 6% |
Disease patterns and progression | 1 | 6% |
New treatment approaches | 1 | 6% |
Gupta V (2026). [PMID: 41957649](https://pubmed.ncbi.nlm.nih.gov/41957649/). *J Med Case Rep*. [Case Report / Case Series]
Spivak I (2026). [PMID: 41530961](https://pubmed.ncbi.nlm.nih.gov/41530961/). *Lupus*. [Gene Therapy / Novel Therapeutics]
Somasundaram A (2026). [PMID: 41949198](https://pubmed.ncbi.nlm.nih.gov/41949198/). *Indian J Dermatol Venereol Leprol*. [Other]
Stokowski T (2025). [PMID: 41278366](https://pubmed.ncbi.nlm.nih.gov/41278366/). *Kidney international reports*. [Case Report / Case Series]
Sainsbury SG (2025). [PMID: 40446498](https://pubmed.ncbi.nlm.nih.gov/40446498/). *Molecular genetics and metabolism*. [Case Report / Case Series]
Pajouhi A (2025). [PMID: 41079045](https://pubmed.ncbi.nlm.nih.gov/41079045/). *Case reports in pediatrics*. [Case Report / Case Series]
Castro M (2025). [PMID: 41245028](https://pubmed.ncbi.nlm.nih.gov/41245028/). *JPGN reports*. [Case Report / Case Series]
Carreño-Hidalgo M (2025). [PMID: 40401402](https://pubmed.ncbi.nlm.nih.gov/40401402/). *American journal of medical genetics. Part A*. [Case Report / Case Series]
Ono H (2025). [PMID: 40801478](https://pubmed.ncbi.nlm.nih.gov/40801478/). *The Journal of dermatology*. [Case Report / Case Series]
Durmuş H (2025). [PMID: 41223033](https://pubmed.ncbi.nlm.nih.gov/41223033/). *Journal of neuromuscular diseases*. [Other]